The Monday Brief — Week of Jul 21, 2026

Boey (trenibotulinumtoxinE) received European approval this week as the first rapid-onset, short-duration neurotoxin for frown lines. The differentiation is real: faster onset and shorter duration than traditional botulinum toxins. For practices, this means new patient conversations around flexibility and shorter commitment—attractive to hesitant or first-time clients. Allergan is positioning this as a premium option. Watch for pricing strategy and how it lands alongside existing injectables. The EU approval signals confidence; U.S. availability timing remains key.

InMode is in the middle of a takeover tug-of-war. Steel Partners tabled a $16.75/share unsolicited bid; the board is now evaluating a rival proposal from the CEO's group. Stock volatility is high, and a court bid to pause the review adds legal complexity. For owners, this matters because InMode is a major device supplier (Morpheus, Lumenis tech). Acquisition uncertainty can slow product roadmaps, support responsiveness, and pricing negotiations. Monitor the deal outcome—consolidation often reshapes vendor relationships and terms. Expect updates in coming weeks.

Cynosure Lutronic launched XERF, a next-generation monopolar RF platform, in Europe and is accelerating adoption in North America. Monopolar RF for non-invasive skin tightening is seeing strong patient demand. The competitive field is crowded—multiple vendors are pushing RF as a workhorse for body and face. For practices, this is a reminder to audit your RF footprint: Are you maximizing existing systems? Is there room for a second platform or upgrade? Pricing and clinical outcomes will drive decisions; don't chase every launch.

Galderma rolled out Alastin regenerative skincare across Japan and key Asia-Pacific markets this week. This is a geographic play, not a new product, but it signals Galderma's commitment to skincare adjacency and international growth. For U.S. practices, Alastin is already available; the news underscores Galderma's scale and distribution muscle. If you're not stocking Alastin or bundling it with injectables/lasers, competitors are. Consider your skincare lineup and whether it complements your core offerings.

Skinvive (hyaluronic acid injectable) earned FDA approval for tech neck lines and other wrinkle indications this week. This is a label expansion that opens new treatment areas and patient messaging. Tech neck is a trendy, relatable concern—good for marketing and patient education. Skinvive sits in the filler/biostimulant space; if you're not offering it, it's another gap in your injectables menu. Approval breadth matters for bundling and upsell conversations.

Market analysts are forecasting GLP-1 aesthetic care (weight-loss drugs repurposed for body contouring, skin tightening, and preventive aging) to reach $2 billion by 2030. This is speculative but signals investor and industry attention. For practices, GLP-1 is a wild card: it could drive demand for skin tightening (RF, ultrasound) and facial rejuvenation as patients lose weight and age differently. Some practices are already offering GLP-1 consultations or partnerships. Stay informed but don't overcommit until the category matures.